Zobrazeno 1 - 10
of 22
pro vyhledávání: '"JAMIE N. CONNARN"'
Autor:
Jamie N. Connarn, Han Witjes, Marielle van Zutphen‐van Geffen, Rik deGreef, Timothy B. Campbell, Kristen Hege, Simon Zhou, Manisha Lamba
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 11, Pp 1687-1697 (2023)
Abstract Idecabtagene vicleucel (ide‐cel; bb2121) is a B‐cell maturation antigen–directed chimeric antigen receptor (CAR) T cell therapy approved for treatment of patients with heavily pretreated relapsed and refractory multiple myeloma. This a
Externí odkaz:
https://doaj.org/article/cedc81b5533d4fda88aaa6bfdc554148
Autor:
Michael S. Gordon, Geoffrey I. Shapiro, John Sarantopoulos, Dejan Juric, Brian Lu, Angeliki Zarotiadou, Jamie N. Connarn, Yvan Le Bruchec, Calin Dan Dumitru, R. Donald Harvey
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
BackgroundCitarinostat (CC-96241; previously ACY-241), an oral inhibitor of histone deacetylases (HDACs) with selectivity for HDAC6, has demonstrated synergistic anticancer activity with paclitaxel in multiple solid tumor models. Combination therapy
Externí odkaz:
https://doaj.org/article/0ab9e0c5140445e598f9434b136856c5
Autor:
Daniel W. Coyne, Hem N. Singh, William T. Smith, Ana Carolina Giuseppi, Jamie N. Connarn, Matthew L. Sherman, Frank Dellanna, Hartmut H. Malluche, Keith A. Hruska
Publikováno v:
Kidney International Reports, Vol 4, Iss 11, Pp 1585-1597 (2019)
Introduction: Patients with end-stage kidney disease (ESKD) exhibit anemia, chronic kidney disease‒mineral bone disorder (CKD–MBD), and cardiovascular disease. The REN-001 and REN-002 phase II, multicenter, randomized studies examined safety, tol
Externí odkaz:
https://doaj.org/article/0bccf5654da24b36b96c0047fa7d3a78
Autor:
JOHN Malona, CLAUDIO CHUAQUI, BORIS M. SELETSKY, LISA BEEBE, SUSAN CANTIN, DANIEL VAN KALKEN, KELLY FAHNOE, ZHIGANG WANG, BETH BROWNING, HILARY SZABO, LOUISE A. KOOPMAN, TAMAS ORAVECZ, JOSEPH J. MCDONALD, FRANCISCO RAMIREZ-VALLE, RAJULA GAUR, KOFI A. MENSAH, MICHAEL THOMAS, JAMIE N. CONNARN, HAIQING HU, MATTHEW D. ALEXANDER, ALAN F. CORIN
Publikováno v:
Translational research : the journal of laboratory and clinical medicine. 249
As an anti-inflammatory strategy, MAPK-activated protein kinase-2 (MK2) inhibition can potentially avoid the clinical failures seen for direct p38 inhibitors, especially tachyphylaxis. CC-99677, a selective targeted covalent MK2 inhibitor, employs a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6afca613da09ae7ab956e9811531b01
https://pubmed.ncbi.nlm.nih.gov/35691544
https://pubmed.ncbi.nlm.nih.gov/35691544
Publikováno v:
Clinical Pharmacology: Advances and Applications. 11:39-50
Background Enasidenib (IDHIFA®, AG-221) is a first-in-class, targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. This was a Phase I/II study evaluating safety, efficacy, and pharmacokinetics/pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e49ed47315a0ebba9a868cd84c28c12
https://doi.org/10.2147/cpaa.s192687
https://doi.org/10.2147/cpaa.s192687
Autor:
Monica Massaro, Deepu Madduri, Donna Reece, Nikhil C. Munshi, Larry D Anderson, A. Oriol, Ibrahim Yakoub-Agha, Katja Weisel, Nina Shah, Noopur Raje, Jesús F. San-Miguel, Hartmut Goldschmidt, Timothy B. Campbell, Kristen Hege, Alessandro Rambaldi, Yi Lin, Michel Delforge, Michele Cavo, Philippe Moreau, Jesus G. Berdeja, Jamie N Connarn, Shari Kaiser, Sagar Lonial, David S. Siegel, Hermann Einsele, Liping Huang, Fabio Petrocca, Payal Patel
Publikováno v:
New England Journal of Medicine
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
BACKGROUND Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigendirected chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d9093ae38097830bb12fa69d8e865a7
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2307
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2307
Publikováno v:
Clinical Pharmacology in Drug Development. 7:465-473
A population pharmacokinetic (PopPK) model of lenalidomide was developed using data pooled from 13 clinical studies (dose range, 5-400 mg) in participants who were considered to have adequate capability for renal excretion of lenalidomide (creatinine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b73ba55b2ea6b5035b2491c8b71f1de1
https://doi.org/10.1002/cpdd.372
https://doi.org/10.1002/cpdd.372
Publikováno v:
Clinical Pharmacology : Advances and Applications
Background Enasidenib (IDHIFA®, AG-221) is a first-in-class, targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. This was a Phase I/II study evaluating safety, efficacy, and pharmacokinetics/pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::671499524f160c002a7050f30c94ebf7
https://pubmed.ncbi.nlm.nih.gov/30858735
https://pubmed.ncbi.nlm.nih.gov/30858735
Autor:
Max S. Wicha, Joseph Burnett, Jamie N. Connarn, Hui Jiang, Ila Myers, Lichao Sun, Fangying Xu, Hasan Korkaya, Yajing Liu, Mari Gasparyan, Ning Zhang, Huining He, Duxin Sun, Chang-Ching Lin
Publikováno v:
Oncotarget
// Lichao Sun 1, 2, * , Joseph Burnett 1, * , Mari Gasparyan 1 , Fangying Xu 1 , Hui Jiang 3 , Chang-Ching Lin 1 , Ila Myers 1 , Hasan Korkaya 4 , Yajing Liu 5 , Jamie Connarn 1 , Huining He 6 , Ning Zhang 6 , Max S. Wicha 5 , Duxin Sun 1 1 Departmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e67b8534a0d650554fff3c533ae2c7cd
http://europepmc.org/articles/PMC5239484
http://europepmc.org/articles/PMC5239484
Autor:
Larry D. Anderson, Yi Lin, Timothy B. Campbell, Fabio Petrocca, Kristen Hege, Payal Patel, David S. Siegel, Sundar Jagannath, Jesús F. San Miguel, Ibrahim Yakoub-Agha, Philippe Moreau, Jesus G. Berdeja, Albert Oriol, Nina Shah, Liping Huang, Noopur Raje, Michel Delforge, Nikhil C. Munshi, Sagar Lonial, Jamie N Connarn
Publikováno v:
Journal of Clinical Oncology. 38:8503-8503
8503 Background: Outcomes are poor in triple-class exposed RRMM patients (pts) who progress on immunomodulatory agents (IMiDs), proteasome inhibitors (PIs), and CD38 antibodies (mAbs). Ide-cel, a BCMA targeted CAR T cell therapy, showed promising tol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3751a54d8a15cd1c1336c5a2f5666a79
https://doi.org/10.1200/jco.2020.38.15_suppl.8503
https://doi.org/10.1200/jco.2020.38.15_suppl.8503